Ilex, MGI deal

MOGN discontinued development of dihydro-5-azacytidine (DHAC), a compound it licensed from ILXO

Read the full 129 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE